Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

Tuyishime, Marina, Carolina Garrido, Shalini Jha, Matt Moeser, Dieter Mielke, Celia LaBranche, David Montefiori, et al. “Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.” J Clin Invest 130, no. 10 (October 1, 2020): 5157–70. https://doi.org/10.1172/JCI135557.

Full Text

Baden, Lindsey R., Daniel J. Stieh, Michal Sarnecki, Stephen R. Walsh, Georgia D. Tomaras, James G. Kublin, M Juliana McElrath, et al. “Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.” The Lancet. Hiv 7, no. 10 (October 2020): e688–98. https://doi.org/10.1016/s2352-3018(20)30229-0.

Full Text

Wu, Fan, Ilnour Ourmanov, Andrea Kirmaier, Sivan Leviyang, Celia LaBranche, Jinghe Huang, Sonya Whitted, Kenta Matsuda, David Montefiori, and Vanessa M. Hirsch. “SIV infection duration largely determines broadening of neutralizing antibody response in macaques.” J Clin Invest 130, no. 10 (October 1, 2020): 5413–24. https://doi.org/10.1172/JCI139123.

Full Text

Korber, Bette, Will M. Fischer, Sandrasegaram Gnanakaran, Hyejin Yoon, James Theiler, Werner Abfalterer, Nick Hengartner, et al. “Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.” Cell 182, no. 4 (August 20, 2020): 812-827.e19. https://doi.org/10.1016/j.cell.2020.06.043.

Full Text

Cottrell, Christopher A., Jelle van Schooten, Charles A. Bowman, Meng Yuan, David Oyen, Mia Shin, Robert Morpurgo, et al. “Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates.” Plos Pathog 16, no. 8 (August 2020): e1008753. https://doi.org/10.1371/journal.ppat.1008753.

Full Text

Antanasijevic, Aleksandar, George Ueda, Philip J. M. Brouwer, Jeffrey Copps, Deli Huang, Joel D. Allen, Christopher A. Cottrell, et al. “Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.” Plos Pathog 16, no. 8 (August 2020): e1008665. https://doi.org/10.1371/journal.ppat.1008665.

Full Text

Mansbach, Rachael A., Srirupa Chakraborty, Kien Nguyen, David Montefiori, Bette Korber, and S. Gnanakaran. “The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State.” Biorxiv, July 26, 2020. https://doi.org/10.1101/2020.07.26.219741.

Full Text

De Rosa, Stephen C., Srilatha Edupuganti, Yunda Huang, Xue Han, Marnie Elizaga, Edith Swann, Laura Polakowski, et al. “Robust antibody and cellular responses induced by DNA-only vaccination for HIV.” Jci Insight 5, no. 13 (July 9, 2020). https://doi.org/10.1172/jci.insight.137079.

Full Text

Shao, Shuai, Wei-Chiao Huang, Cuiyan Lin, Mark D. Hicar, Celia C. LaBranche, David C. Montefiori, and Jonathan F. Lovell. “An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice.” Ann Biomed Eng 48, no. 7 (July 2020): 1991–2001. https://doi.org/10.1007/s10439-019-02398-8.

Full Text

Kasturi, Sudhir Pai, Mohammed Ata Ur Rasheed, Colin Havenar-Daughton, Mathew Pham, Traci Legere, Zarpheen Jinnah Sher, Yevgeny Kovalenkov, et al. “3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.” Sci Immunol 5, no. 48 (June 19, 2020). https://doi.org/10.1126/sciimmunol.abb1025.

Full Text

Pages